Lawrence Tawiah, PA
Medical · Salisbury, MDNPI 1508223108
Payments from drug & device makers
Across 148 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$458
- Novo Nordisk$425
- Lilly USA, LLC$335
- Pfizer$164
- Takeda Pharmaceuticals U.S.A., Inc.$153
- Sumitomo Pharma America, Inc.$139
- plus $849 from 15 others
What the payments were for
- Food & beverage$2,525100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 32 | $458 |
| Novo Nordisk | 28 | $425 |
| Lilly USA, LLC | 16 | $335 |
| Pfizer | 9 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $153 |
| Sumitomo Pharma America, Inc. | 6 | $139 |
| Novartis | 6 | $126 |
| AstraZeneca | 7 | $106 |
| AbbVie | 5 | $95 |
| Boehringer Ingelheim | 5 | $93 |
| Dexcom, Inc. | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Exact Sciences | 3 | $57 |
| Merck | 3 | $48 |
| Johnson & Johnson | 3 | $46 |
| GSK | 2 | $33 |
| Boston Scientific | 1 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Soleno Therapeutics, Inc. | 1 | $15 |
How this compares
$2,525 in reported general payments places this provider in the 75th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $125,109 |
| JardianceEmpagliflozin | 74 | $102,852 |
| EliquisApixaban | 35 | $40,661 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $36,880 |
| Repatha SureclickEvolocumab | 20 | $29,720 |
| FarxigaDapagliflozin Propanediol | 30 | $28,836 |
| MounjaroTirzepatide | 25 | $28,832 |
| EntrestoSacubitril/Valsartan | 12 | $19,584 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $18,930 |
| XareltoRivaroxaban | 11 | $18,307 |
| JanuviaSitagliptin Phosphate | 12 | $16,609 |
| GemtesaVibegron | 15 | $12,366 |
| Praluent PenAlirocumab | 11 | $10,017 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,571 |
| TradjentaLinagliptin | 14 | $7,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $425 | $125,10979 claims |
| Boehringer IngelheimJardiance, Tradjenta | $93 | $110,21088 claims |
| PfizerEliquis, Paxlovid | $164 | $42,09151 claims |
| GSKTrelegy Ellipta | $33 | $36,88055 claims |
| AstraZenecaFarxiga, Symbicort | $106 | $31,62043 claims |
| Lilly USA, LLCMounjaro | $335 | $28,83225 claims |
| MerckJanuvia, Belsomra | $48 | $22,09425 claims |
| NovartisEntresto | $126 | $19,58412 claims |
| Johnson & JohnsonXarelto | $46 | $18,30711 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $139 | $12,36615 claims |
| AbbVieSynthroid | $95 | $91418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 543 medical providers in Maryland.
Other medical in Salisbury
- Brandon McMullenSalisbury$9K
- Vincent LewisSalisbury$8K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.